Astatine-211 based radionuclide therapy: Current clinical trial landscape

202373 citationsReviewgold Open Access

Authors

Per Albertsson · University of Gothenburg

Tom Bäck · University of Gothenburg

Karin Bergmark · University of Gothenburg

Andreas Hallqvist · Sahlgrenska University Hospital

Mia Johansson · University of Gothenburg

Emma Aneheim · University of Gothenburg

Sture Lindegren ·

Abstract

Astatine-211 (<sup>211</sup>At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe ongoing trials, and discuss future prospects.

Topics & Keywords

Radiopharmaceutical Chemistry and Applications Medical Imaging Techniques and Applications Lung Cancer Treatments and Mutations

Publication Details

Published in: Frontiers in Medicine

Volume 9, pp. 1076210-1076210

DOI: 10.3389/fmed.2022.1076210

Field-Weighted Citation Impact: 16.68

Command Palette

Astatine-211 based radionuclide therapy: Current clinical trial landscape

Authors

Abstract

Topics & Keywords

Publication Details